Incyte Corporation (INCY)’s Financial Results Comparing With Titan Pharmaceuticals Inc. (NASDAQ:TTNP)

Incyte Corporation (NASDAQ:INCY) and Titan Pharmaceuticals Inc. (NASDAQ:TTNP) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incyte Corporation 1.88B 9.65 109.49M 0.50 169.46
Titan Pharmaceuticals Inc. 5.44M 4.25 9.46M -2.66 0.00

Demonstrates Incyte Corporation and Titan Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Incyte Corporation 5.82% 6.2% 4.4%
Titan Pharmaceuticals Inc. -173.90% -904.1% -123.4%

Risk & Volatility

Incyte Corporation’s volatility measures that it’s 39.00% more volatile than S&P 500 due to its 1.39 beta. Titan Pharmaceuticals Inc.’s 0.75 beta is the reason why it is 25.00% less volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Incyte Corporation are 4.3 and 4.3. Competitively, Titan Pharmaceuticals Inc. has 5.2 and 4.6 for Current and Quick Ratio. Titan Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Incyte Corporation.

Analyst Recommendations

In next table is shown Incyte Corporation and Titan Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Incyte Corporation 0 5 5 2.50
Titan Pharmaceuticals Inc. 0 0 0 0.00

Incyte Corporation has an average price target of $85.33, and a 0.63% upside potential.

Insider & Institutional Ownership

Institutional investors held 94% of Incyte Corporation shares and 5.2% of Titan Pharmaceuticals Inc. shares. Insiders held 0.3% of Incyte Corporation shares. On the other hand, insiders held about 3.1% of Titan Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Incyte Corporation -1.69% 5.98% 29.88% 15.29% 2.79% 34.31%
Titan Pharmaceuticals Inc. -5.98% 40.65% -15.94% -62.11% -70.03% 29.3%

For the past year Incyte Corporation has stronger performance than Titan Pharmaceuticals Inc.

Summary

Incyte Corporation beats on 11 of the 12 factors Titan Pharmaceuticals Inc.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the companyÂ’s clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.